Core Viewpoint - SiBone (SIBN) is identified as a potential stock pick due to a recent "golden cross" event, indicating a bullish trend from a technical perspective [1]. Technical Analysis - A "golden cross" occurs when a short-term moving average (50-day) crosses above a long-term moving average (200-day), suggesting a potential bullish breakout [2]. - The formation of a golden cross involves three stages: a downtrend that bottoms out, the crossover of moving averages, and subsequent upward momentum [3]. - The golden cross is contrasted with a "death cross," which indicates potential bearish momentum [3]. Performance Metrics - SIBN has experienced a rally of 26.7% over the past four weeks, indicating strong upward momentum [4]. - Currently, SIBN holds a 3 (Hold) rating on the Zacks Rank, suggesting it may be poised for further breakout [4]. - Earnings expectations for SIBN have improved, with five upward revisions and no downward changes in the last 60 days, leading to an increase in the Zacks Consensus Estimate [4]. Investment Consideration - Given the significant technical indicators and positive earnings estimate movements, SIBN is recommended for inclusion on investors' watchlists [6].

Core Insights - The Cooper Companies, Inc. (COO) reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.15, an 11% year-over-year increase, surpassing the Zacks Consensus Estimate of $1.11 by 3.6% [1] - Revenues reached $1.065 billion, reflecting a 5% year-over-year increase on a reported basis and a 3% organic growth, also beating the Zacks Consensus Estimate by 0.5% [2] Financial Performance - GAAP EPS for the quarter was 43 cents, down 27% year over year [1] - Adjusted gross profit rose 3.4% to $704.7 million, but adjusted gross margin contracted by almost 70 basis points to 66% due to an unfavorable product mix and tariff headwinds [14] - Selling, general and administrative expenses increased by 7.1% to $419.2 million, while research and development expenses rose by 9.8% to $41.4 million [15] - Adjusted operating profit totaled $288 million, reflecting a 9.4% increase from the previous year, with an adjusted operating margin expanding by 110 basis points to 27% [15] Segment Performance - CooperVision (CVI) segment revenues were $709.6 million, up 5% year over year, driven by MyDay contract wins and strong MiSight sales [4][7] - The CVI segment's Toric and multifocal revenues totaled $344.6 million, up 7% year over year, while Sphere and other revenues reached $365 million, up 3% year over year [8] - The CooperSurgical (CSI) segment's revenues totaled $355.6 million, up 4% year over year, with Office and surgical revenues at $214.6 million, up 6% [11][12] Geographic Performance - Americas' revenues totaled $285.1 million, up 5% year over year, while EMEA revenues amounted to $277.1 million, up 8% year over year [9] - Asia Pacific revenues were $147.4 million, down 1% year over year, primarily due to a 28% decline in China [10] Future Outlook - For fiscal 2026, the company expects revenues in the range of $4,299-$4,338 million, indicating an organic improvement of 3-4% from the prior year [17] - The CVI segment's revenues are projected to be between $2,900-$2,925 million, suggesting an organic improvement of 4.5-5.5% [17] - The CSI segment's revenues are anticipated to be in the range of $1,399-$1,413 million, indicating an organic improvement of 4-5% [18] Growth Catalysts - The company is set to benefit from the global rollout of the MyDay portfolio, expanded private-label wins, and new product launches in 2026 [20] - MiSight is expected to deliver another 20-25% growth, supported by launches in Europe and Japan [20] - The company aims to unlock approximately $50 million in annual savings through AI-driven operational efficiencies [21]

Core Insights - Deep Sail Capital's third-quarter fund performance showed a net return of 5.8%, outperforming the Russell 2000 Mid Cap Growth Index's 0.4% but lagging behind the Russell 2000 Index's 12.4% gain [1] - Year-to-date, the fund achieved an 18.1% return net of fees, compared to 10.2% and 10.4% for the respective indexes [1] - The long portfolio was a significant contributor to the fund's performance, while the short portfolio underperformed due to market conditions [1] Company Focus: ClearPoint Neuro, Inc. (NASDAQ:CLPT) - ClearPoint Neuro, Inc. is highlighted as a key stock in Deep Sail Capital's portfolio, focusing on minimally invasive surgical procedures [2] - The stock experienced a one-month return of -11.07% and a 52-week gain of 4.30%, closing at $14.06 with a market capitalization of $418.261 million on December 04, 2025 [2] - ClearPoint Neuro was one of the largest contributors to the fund's performance in Q3, alongside Kraken Robotics [3] Industry Developments - ClearPoint Neuro is set to benefit from uniQure's strong trial results for its gene therapy AMT-130, which showed a ~75% slowing of Huntington's disease progression over three years [3] - The SmartFlow Cannula system provided by ClearPoint Neuro will be utilized in uniQure's treatments, indicating potential for significant milestone revenues and increased usage of their system in the future [3] - Despite its potential, ClearPoint Neuro is not among the 30 most popular stocks among hedge funds, with 10 hedge fund portfolios holding the stock at the end of Q3, unchanged from the previous quarter [4]

Core Insights - Medtronic plc (MDT) has received FDA approval for the Hugo robotic-assisted surgery (RAS) system, enhancing urologic surgical procedures and providing a versatile platform for minimally invasive care [1][9]. Company Developments - The Hugo RAS system builds on Medtronic's existing surgical offerings, including the Touch Surgery ecosystem, to create a connected operating room environment [2]. - Following the announcement on December 3, MDT shares increased by 0.02%, closing at $101.99, indicating a positive market reaction [3]. - Medtronic's current market capitalization stands at $130.73 billion, with an earnings yield of 5.5%, significantly higher than the industry average of 0.1% [4]. Product Features - The Hugo RAS system features a modular design that allows for flexible deployment across various care settings, enhancing utilization and customization for surgeons [5]. - The system includes an open surgeon console that improves situational awareness, reduces physical strain, and offers better training opportunities for surgical teams [5][6]. - It integrates with the Touch Surgery ecosystem, providing pre-operative training, remote tele-proctoring, and AI-driven post-operative insights, making Medtronic the only company to support all surgical modalities [6]. Market Potential - The global urology robotic surgery market is valued at $2 billion in 2024, with a projected CAGR of 8.7% through 2033, driven by the demand for minimally invasive surgeries [10]. - Medtronic plans to expand the Hugo RAS system's applications in the U.S. to include general and gynecologic surgical procedures following its initial urology clearance [7]. Stock Performance - Over the past six months, MDT shares have increased by 16.6%, outperforming the industry, which saw a decline of 1.3% [12].

Core Viewpoint - Aethlon Medical, Inc. has entered into a securities purchase agreement for a private placement to raise approximately $3.3 million through the sale of common stock and warrants, aimed at supporting its development of medical products for cancer and infectious diseases [1][3]. Group 1: Securities Purchase Agreement - The company will sell 595,897 shares of common stock and warrants to purchase up to 1,042,820 additional shares, with a combined effective offering price of $4.03 per share [1]. - The warrants will have an exercise price of $4.03 and will be exercisable upon shareholder approval, expiring five and a half years after such approval [1]. Group 2: Warrant Inducement Agreement - Aethlon has entered into a warrant inducement agreement to allow the investor to exercise certain outstanding warrants at a reduced price of $4.03, which includes 155,000 shares from March 2025 Warrants and 55,555 shares from September 2025 Warrants [2]. - In exchange for the immediate exercise of these warrants, the company will issue new unregistered warrants for an additional 368,471 shares, also at an exercise price of $4.03 [2]. Group 3: Financial Details - The gross proceeds from the private placement and warrant inducement are estimated to be around $3.3 million before deducting fees and expenses [3]. - The offering is expected to close on or about December 8, 2025, pending customary closing conditions [3]. Group 4: Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, focused on developing the Hemopurifier to address unmet needs in oncology and infectious diseases [6].

"Company† ) (NYSE: OWLT), the pioneer of smart infant monitoring, today announces that Dream Sockâ,,¢ is now available for families across Australia and New Zealand. Dream Sock recently received approval from Australia's Therapeutic Goods Administration (TGA), meeting rigorous medical device standards in the region. With this milestone achieved, families can now purchase Dream Sock through Owlet's local website and select retail partners. "Bringi. SYDNEY--(BUSINESS WIRE)---- $owlt #babymonitor--Owlet, Inc. ...

Core Insights - IceCure Medical has received a Notice of Allowance for a patent related to its Cryogen Flow Control technology, enhancing the efficacy and precision of cryoablation procedures [1][3] - The ProSense® Cryoablation System is the first medical device authorized by the FDA for treating low-risk breast cancer in women aged 70 and older [4] Company Developments - IceCure's intellectual property portfolio has grown to 55 patents granted and allowed globally, reflecting its commitment to technological innovation [3] - The company is focused on developing next-generation cryoablation systems, including the XSense™ system, which utilizes liquid nitrogen for improved patient outcomes [3][5] Technology and Innovation - The Cryogen Flow Control technology allows for precise temperature regulation during cryoablation, which is critical for treatment efficacy and tissue safety [3] - Advanced cryogen flow control systems may incorporate functionalities such as navigation and mapping support within the patient's anatomy, broadening their application in cryosurgical tools [3] Market Position - IceCure Medical's ProSense® system is marketed and sold worldwide, with regulatory approvals in key markets including the U.S., Europe, and Asia [5]

NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical- ...

Core Viewpoint - Iridex Corporation, a leader in laser-based medical systems for ophthalmology, will participate in the Sidoti Year-End Virtual Investor Conference on December 11, 2025 [1][2]. Company Overview - Iridex Corporation specializes in developing, manufacturing, and marketing innovative laser-based medical systems, including capital equipment and consumable probes for the ophthalmology market [3]. - The company's proprietary MicroPulse technology provides effective laser treatment while minimizing tissue damage, making it a safe option for treating sight-threatening eye conditions [3]. - Iridex's product line is utilized for treating glaucoma, diabetic macular edema (DME), and other retinal diseases, with sales occurring in the U.S. through a direct sales force and internationally via independent distributors in over 100 countries [3].

Core Insights - Edwards Lifesciences is a leading company in the medical technology sector, focusing on heart valve therapies and critical care monitoring, particularly for structural heart diseases like aortic stenosis and mitral regurgitation [1] Company Performance - On December 4, 2025, BTIG upgraded Edwards Lifesciences to a "Buy" recommendation, with the stock priced at $85.78, reflecting confidence in the company's sustainable growth strategy and strong market position [2] - BTIG also raised the price target for Edwards Lifesciences from $100 to $103, indicating optimism about the company's ability to leverage emerging opportunities and expand its market presence [3] - The stock has shown resilience, currently priced at $85.78, with a recent increase of 2.14%, and has fluctuated between $65.94 and $87.40 over the past year, demonstrating stable performance [4] Market Position - Edwards Lifesciences has a market capitalization of approximately $50.37 billion, highlighting its significant presence in the medical technology industry [5] - The company has a trading volume of 2,385,439 shares, indicating strong investor interest and solidifying its leadership in heart valve therapies and critical care solutions [5]